INS and Hypoglycemia: Certainly, relative to sulfonylurea (SU) or insulin, the lower risk of hypoglycaemia with AHA is clear and widely accepted.5, 6, 7, 8, 9 However, relative to placebo, efficacy‐focused studies have been unable to delineate hypoglycaemia risk with these newer AHA, mainly due to the use of background SU and insulin.